Table 2.
Comparison of clinical and laboratory characteristics between DM/CADM/PM patients with RP-ILD and C-ILD.
| Variables | RP-ILD n = 117 | C-ILD n = 191 | P-value |
|---|---|---|---|
| DIAGNOSIS | |||
| DM, no. (%) | 48 (41.0) | 79 (41.4) | 0.954 |
| CADM, no. (%) | 60 (51.3) | 88 (46.1) | 0.375 |
| PM, no. (%) | 9 (7.7) | 24 (12.6) | 0.180 |
| DEMOGRAPHICS | |||
| Female, no. (%) | 87 (74.4) | 145 (75.9) | 0.758 |
| Age at onset, years | 54.1 ± 12.7 | 50.1 ± 12.9 | 0.009* |
| Duration of ILD, months | 2.0 ± 0.9 | 31.6 ± 59.4 | 0.000* |
| CLINICAL VARIABLES | |||
| Fever, no. (%) | 74 (63.2) | 71 (37.2) | 0.000* |
| Gottron's sign/papules, no. (%) | 81 (69.2) | 137 (71.7) | 0.640 |
| Periungual erythema, no. (%) | 26 (22.2) | 23 (12.0) | 0.018* |
| Skin ulceration, no. (%) | 13 (11.1) | 6 (3.1) | 0.005* |
| Muscle weakness, no. (%) | 56 (47.9) | 124 (64.9) | 0.003* |
| Subcutaneous/mediastinal emphysema, no. (%) | 7 (6.0) | 0 (0.0) | 0.001* |
| Malignancy, no. (%) | 4 (3.4) | 18 (9.4) | 0.047* |
| LABORATORY FEATURES | |||
| Lymphocytes, × 109/L | 1.1 ± 0.7 | 1.5 ± 0.9 | 0.000* |
| CK, U/L | 65 (30.5,274.5) | 72 (34,563) | 0.448 |
| LDH, U/L | 324 (221,501) | 281 (193.8,395) | 0.014* |
| AST, U/L | 38 (21.5,84.5) | 30 (20,60) | 0.029* |
| CRP, mg/dL | 7.6 (2.4,31.0) | 5.0 (1.9,13.0) | 0.019* |
| Ferritin (ng/mL)a | 1,065 (584.1,2690) | 307.9 (129.8,881.3) | 0.001* |
| Elevated CEA, no. (%) | 37 (31.6) | 22 (11.5) | 0.000* |
| Elevated NSE, no. (%) | 60 (51.2) | 70 (36.6) | 0.012* |
| Elevated CYFRA21-1, no. (%) | 78 (66.7) | 73 (38.2) | 0.000* |
Continuous data were expressed as the mean ± standard error or medians (interquartile range). Binary data were presented as n (percentage) of the patients.
a
49 patients of 117, 68 values missing in RP-ILD group;
*
< 0.05. IIM, idiopathic inflammatory myopathy; ILD, interstitial lung disease; RP-ILD, rapidly progressive ILD; C-ILD, Chronic ILD; CK, creatine kinase; LDH, lactate dehydrogenase; AST, aspartate aminotransferase; CRP, C-reactive protein, CEA, carcinoembryogenic antigen; NSE, neuron-specific enolase; CYFRA21-1, cytokeratin-19 fragment.